For Trump's executive order on making the MMR single antigen vaccines, mRNA vaccines are already in development.
NIAID’s Vaccine Research Center has a single-disease mRNA mumps vaccine in development.
In late 2025, Frederick National Laboratory solicited an FDA-required GLP repeat-dose toxicology study for the investigational mRNA mumps vaccine. That work was awarded in January 2026.
The NIH mRNA mumps program was already moving through FDA-enabling preclinical development before Trump issued his order.
The NIH mumps vaccine's intellectual-property trail leads to Mevox, whose CEO is one of the NIH vaccine inventors and a former Moderna scientist and Moderna mRNA-vaccine inventor.
The NIH patent itself specifically identifies Moderna's LNP technology as one possible means of delivering the mumps antigen as mRNA.
Frederick says the actual vaccine now in development uses five lipids, two proprietary, but has not publicly identified their owners.

📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD